These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9703756)

  • 1. Dopamine D1 receptor agonists as antiparkinson drugs.
    Mailman RB; Nichols DE
    Trends Pharmacol Sci; 1998 Jul; 19(7):255-6. PubMed ID: 9703756
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.
    Williams M; Wright S; Lloyd GK
    Trends Pharmacol Sci; 1997 Sep; 18(9):307-10. PubMed ID: 9345846
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
    Gulwadi AG; Korpinen CD; Mailman RB; Nichols DE; Sit SY; Taber MT
    J Pharmacol Exp Ther; 2001 Feb; 296(2):338-44. PubMed ID: 11160615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dopamine agonists in the management of Parkinson disease. D1- and D2-receptors regulate the motor function].
    Nervenarzt; 1994 Jul; 65(7 Suppl Dopaminago):1-4. PubMed ID: 9431361
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
    Blanchet PJ; Fang J; Gillespie M; Sabounjian L; Locke KW; Gammans R; Mouradian MM; Chase TN
    Clin Neuropharmacol; 1998; 21(6):339-43. PubMed ID: 9844789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
    Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
    Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
    Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.
    Asin KE; Domino EF; Nikkel A; Shiosaki K
    J Pharmacol Exp Ther; 1997 Apr; 281(1):454-9. PubMed ID: 9103530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
    Kuno S
    Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection in PD--a role for dopamine agonists?
    Schapira AH
    Neurology; 2003 Sep; 61(6 Suppl 3):S34-42. PubMed ID: 14504378
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopamine agonists in early therapy for Parkinson disease: promise and problems.
    Tanner CM
    JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895
    [No Abstract]   [Full Text] [Related]  

  • 13. The missing, the short, and the long: Levodopa responses and dopamine actions.
    Albin RL; Leventhal DK
    Ann Neurol; 2017 Jul; 82(1):4-19. PubMed ID: 28543679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old and new dopamine agonists in Parkinson's disease. Proceedings of an international congress. Pisa, Italy, December 1993.
    J Neural Transm Suppl; 1995; 45():1-321. PubMed ID: 8847537
    [No Abstract]   [Full Text] [Related]  

  • 15. Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.
    Marek K; Jennings D; Seibyl J
    Neurology; 2003 Sep; 61(6 Suppl 3):S43-8. PubMed ID: 14504379
    [No Abstract]   [Full Text] [Related]  

  • 16. [Presentation].
    García-Ruiz PJ; Luquin MR; Martínez-Castrillo JC
    Rev Neurol; 2012; 55 Suppl 1():S1. PubMed ID: 23169226
    [No Abstract]   [Full Text] [Related]  

  • 17. Preclamol and parkinsonian fluctuations.
    Pirtosek Z; Merello M; Carlsson A; Stern G
    Clin Neuropharmacol; 1993 Dec; 16(6):550-4. PubMed ID: 9377590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New dopamine agonists on the horizon.
    Heins JR
    S D J Med; 1997 Jul; 50(7):239-40. PubMed ID: 9240032
    [No Abstract]   [Full Text] [Related]  

  • 20. Did levodopa vs. dopamine agonist trials teach us when and how to start symptomatic therapy?
    Waters C
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S31-3. PubMed ID: 20083002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.